-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Equal-Weight on Amphastar Pharma, Lowers Price Target to $20

Benzinga·06/03/2026 13:10:35
Listen to the news
Barclays analyst Glen Santangelo maintains Amphastar Pharma (NASDAQ:AMPH) with a Equal-Weight and lowers the price target from $23 to $20.